Clinical trial NCT05920356 · Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT05920356 (phase III) is «recruiting» on ClinicalTrials.gov.

Condition: Non-Small Cell Lung Cancer (NSCLC) · Registered interventions: Sotorasib, Pembrolizumab · Recorded dates (source): 2023-11-16, 2027-06-30, 2023-06-27, 2026-09-11.

Study summary (source: ClinicalTrials.gov):

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Source: https://clinicaltrials.gov/study/NCT05920356